[
  {
    "ts": null,
    "headline": "Hims & Hers to shut down dermatology business Apostrophe",
    "summary": "Hims & Hers Health would discontinue Apostrophe, its personalized acne treatments dermatology business, the company said on Friday. Apostrophe is being shut down to simplify its ...",
    "url": "https://finnhub.io/api/news?id=cf6ed5ff1c9bc055acd29c23c90e09ed5f30917b73838ee55f49bd4c4f50e141",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741371801,
      "headline": "Hims & Hers to shut down dermatology business Apostrophe",
      "id": 133101018,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "Hims & Hers Health would discontinue Apostrophe, its personalized acne treatments dermatology business, the company said on Friday. Apostrophe is being shut down to simplify its ...",
      "url": "https://finnhub.io/api/news?id=cf6ed5ff1c9bc055acd29c23c90e09ed5f30917b73838ee55f49bd4c4f50e141"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly CEO's Total Compensation Rose 10% in 2024",
    "summary": "By Connor Hart Eli Lilly Chief Executive David Ricks annual compensation rose to $29.2 million in 2024, a 10% increase from the $26.2 million he received a year earlier. Ricks' payout included...",
    "url": "https://finnhub.io/api/news?id=7fc040f6a37094e8331fb719d60c96b241481966694181844151c1802bb255eb",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741368667,
      "headline": "Eli Lilly CEO's Total Compensation Rose 10% in 2024",
      "id": 133100689,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "By Connor Hart Eli Lilly Chief Executive David Ricks annual compensation rose to $29.2 million in 2024, a 10% increase from the $26.2 million he received a year earlier. Ricks' payout included...",
      "url": "https://finnhub.io/api/news?id=7fc040f6a37094e8331fb719d60c96b241481966694181844151c1802bb255eb"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly & Co. stock underperforms Friday when compared to competitors",
    "summary": "Eli Lilly & Co. stock underperforms Friday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=1669bd450fce007c6c646aa587ef3cdd44897faa6e1013d3c65397ce46c2c2cb",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741365060,
      "headline": "Eli Lilly & Co. stock underperforms Friday when compared to competitors",
      "id": 133103941,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Eli Lilly & Co. stock underperforms Friday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=1669bd450fce007c6c646aa587ef3cdd44897faa6e1013d3c65397ce46c2c2cb"
    }
  },
  {
    "ts": null,
    "headline": "US judge denies injunction, restricting copies of Lilly weight-loss drug",
    "summary": "A U.S. federal judge has refused to allow compounding pharmacies to keep making copies of Eli Lilly's popular weight-loss and diabetes drugs Zepbound and Mounjaro in the United States. ...",
    "url": "https://finnhub.io/api/news?id=cc553cff2f207a117c2cbf42af4f3dd38c9cc7d1bf37a418d5038dfdce4ddf0c",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741350527,
      "headline": "US judge denies injunction, restricting copies of Lilly weight-loss drug",
      "id": 133093364,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "A U.S. federal judge has refused to allow compounding pharmacies to keep making copies of Eli Lilly's popular weight-loss and diabetes drugs Zepbound and Mounjaro in the United States. ...",
      "url": "https://finnhub.io/api/news?id=cc553cff2f207a117c2cbf42af4f3dd38c9cc7d1bf37a418d5038dfdce4ddf0c"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Vs. Johnson & Johnson: Who's The Better Bargain For Investors",
    "summary": "Discover the strengths & weaknesses of healthcare giants Johnson & Johnson and Pfizer. Find out which stock is more promising for long-term investors.",
    "url": "https://finnhub.io/api/news?id=a2dd56b014439c476c94b99818c078982b06255bce3559661474d82856504139",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741340054,
      "headline": "Pfizer Vs. Johnson & Johnson: Who's The Better Bargain For Investors",
      "id": 133090283,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1398811731/image_1398811731.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Discover the strengths & weaknesses of healthcare giants Johnson & Johnson and Pfizer. Find out which stock is more promising for long-term investors.",
      "url": "https://finnhub.io/api/news?id=a2dd56b014439c476c94b99818c078982b06255bce3559661474d82856504139"
    }
  },
  {
    "ts": null,
    "headline": "In Rotten Market, Top Funds Harvest Apple Stock — And 10 Others",
    "summary": "In Rotten Market, Top Funds Harvest Apple Stock — And 10 Others",
    "url": "https://finnhub.io/api/news?id=bf8c820db5a7371d0da6d2d6545ef166640fbb642747f8945dd9bd6149270a55",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741334456,
      "headline": "In Rotten Market, Top Funds Harvest Apple Stock — And 10 Others",
      "id": 133086634,
      "image": "",
      "related": "LLY",
      "source": "DowJones",
      "summary": "In Rotten Market, Top Funds Harvest Apple Stock — And 10 Others",
      "url": "https://finnhub.io/api/news?id=bf8c820db5a7371d0da6d2d6545ef166640fbb642747f8945dd9bd6149270a55"
    }
  },
  {
    "ts": null,
    "headline": "ClearBridge Global Growth Strategy Q4 2024 Commentary",
    "summary": "During the fourth quarter, the ClearBridge Global Growth Strategy outperformed its MSCI ACWI benchmark. Click here to read the full commentary.",
    "url": "https://finnhub.io/api/news?id=59930a1a9918ccb79efd1b65488418aa3dd6328949c2ef1595ec3cf14694e035",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741322100,
      "headline": "ClearBridge Global Growth Strategy Q4 2024 Commentary",
      "id": 133085717,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1385299427/image_1385299427.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "During the fourth quarter, the ClearBridge Global Growth Strategy outperformed its MSCI ACWI benchmark. Click here to read the full commentary.",
      "url": "https://finnhub.io/api/news?id=59930a1a9918ccb79efd1b65488418aa3dd6328949c2ef1595ec3cf14694e035"
    }
  }
]